ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

Core Insights - ANI Pharmaceuticals, Inc. announced preclinical data demonstrating the efficacy of Purified Cortrophin® Gel in reducing inflammatory molecules in an experimental autoimmune uveitis (EAU) mouse model, indicating a significant dose-dependent effect [2][3][4] Group 1: Preclinical Data and Results - The study utilized an EAU mouse model to assess the impact of four different doses (4, 40, 160, or 400 U/kg) of repository corticotrophin injection, showing the greatest suppression of EAU at the highest dose of 400 U/kg [3] - Cortrophin Gel treatment at 400 U/kg significantly suppressed retinal damage caused by EAU, comparable to α-MSH treatment, when compared to a placebo [3] Group 2: Presentation and Commitment - The data was presented at the ARVO 2025 annual meeting, highlighting ANI's commitment to clinical research and the scientific evidence supporting Cortrophin Gel's mechanism of action [4][5] - The presentation was led by Dr. Andrew W. Taylor, emphasizing innovative strategies for modulating ocular inflammation [6] Group 3: Product Indication and Usage - Cortrophin Gel is indicated for severe acute and chronic allergic and inflammatory conditions affecting the eye, including various forms of uveitis and conjunctivitis [8] - The product is administered subcutaneously or intramuscularly, underscoring its therapeutic application in ophthalmology [8]